Anidulafungin ? state of affairs from a clinical perspective
- 1 May 2007
- Vol. 50 (s1) , 38-43
- https://doi.org/10.1111/j.1439-0507.2007.01378.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin SusceptibilityAntimicrobial Agents and Chemotherapy, 2006
- Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during TherapyAntimicrobial Agents and Chemotherapy, 2006
- Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitisJournal of Antimicrobial Chemotherapy, 2006
- In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to FluconazoleJournal of Clinical Microbiology, 2005
- Initial results from a longitudinal international surveillance programme for anidulafungin (2003)Journal of Antimicrobial Chemotherapy, 2004
- In Vitro Activity of Anidulafungin against Selected Clinically Important Mold IsolatesAntimicrobial Agents and Chemotherapy, 2004
- Echinocandin antifungal drugsThe Lancet, 2003
- Invasive Oesophageal CandidiasisDrugs, 2003
- CaspofunginDrugs, 2003
- In Vitro Activity of Two Echinocandin Derivatives, LY303366 and MK-0991 (L-743,792), Against Clinical Isolates of Aspergillus, Fusarium, Rhizopus, and Other Filamentous FungiDiagnostic Microbiology and Infectious Disease, 1998